Market Data
Market Cap₹35,540.29 Cr.
52W High₹2,420
Current Price₹2,187.2
52W Low₹1,086.8
Down from 52W High9.6 %
Face Value₹5
Performance
ROCE9.62 %
ROE8.28 %
EPS (TTM)₹6.55
EPS Prev Qtr₹10.23
EPS Last Year₹4.81
EBITDA Qtr₹137 Cr.
Book Value₹304
Financial Health
Debt/Equity0.43
Debt/Profit5.13
Total Assets₹8,615 Cr.
Promoter Holding49.08 %
Earning Power6.34 %
Valuation
Stock P/E86.79
Industry P/E33.81
Price to Book7.19
Price to Sales9.97
Graham Number₹415.31
Key Metrics
Face Value
₹5
About Wockhardt Ltd
Healthcare · Pharmaceuticals
Wockhardt Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹5. Market cap ₹35,540.29 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a healthy promoter holding of 49.08%, indicating strong control and alignment of interests.
- The company maintains a moderate debt-to-equity ratio of 0.43, suggesting manageable leverage levels.
Weaknesses
- The P/E ratio of 81.87 is significantly high, indicating that the stock may be overvalued relative to its earnings.
- The P/B ratio of 6.79 suggests that the market values the company at a premium compared to its book value.
- The ROCE of 9.62% and ROE of 8.38% are relatively low, indicating less efficient use of capital and lower profitability.
- The company does not currently offer a dividend yield, which may be a concern for income-focused investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 782 | 888 | 965 | 929 |
| ↳ QoQ Growth | - | +13.6% | +8.7% | -3.7% |
| Expenses | 657 | 776 | 793 | 792 |
| Operating Profit | 125 | 112 | 172 | 137 |
| OPM % | 15.98% | 12.61% | 17.82% | 14.75% |
| Other Income | 21 | 25 | 45 | 31 |
| Interest | 55 | 60 | 50 | 52 |
| Depreciation | 53 | 65 | 53 | 55 |
| EBITDA | 178 | 177 | 225 | 192 |
| EBITDA Margin % | 22.76% | 19.93% | 23.32% | 20.67% |
| Profit Before Tax | 91 | 67 | 189 | 116 |
| Tax % | 9.89% | 8.96% | 13.23% | 7.76% |
| Net Profit | 82 | 61 | 164 | 107 |
| ↳ QoQ Growth | - | -25.6% | +168.9% | -34.8% |
| EPS | 4.81 | 3.61 | 10.23 | 6.55 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 81 | 81 |
| Reserves | 4272 | 4859 |
| Borrowings | 2021 | 2125 |
| Other Liabilities | 1761 | 1550 |
| Total Liabilities | 8135 | 8615 |
| Fixed Assets | 1718 | 4499 |
| CWIP | 513 | 671 |
| Investments | 422 | 412 |
| Other Assets | 5482 | 3033 |
| Total Assets | 8135 | 8615 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 390 |
| Cash from Investing Activity | -241 |
| Cash from Financing Activity | -54 |
| Net Cash Flow | 95 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 49.08% | 49.08% | 49.08% | 49.08% |
| FIIs % | 7.1% | 6.99% | 7.09% | 7.22% |
| DIIs % | 11.01% | 10.55% | 10.96% | 9.23% |
| Public % | 26.1% | 26.52% | 25.89% | 27.31% |
| No. of Shareholders | 1,37,946 | 1,42,274 | 1,39,016 | 1,66,518 |
Major Shareholders (>1%)
- Tata Mutual Fund - Tata Small Cap FundPublic Shareholding2.03%
- Rekha JhunjhunwalaPublic Shareholding1.75%
- Hsbc Mutual Fund - Hsbc Small Cap FundPublic Shareholding1.30%
- 3p India Equity Fund 1Public Shareholding1.15%
As of 2026-06-30View all shareholders →